Project Grant R35GM153307

Award Date 8/1/24
Completion Date 7/31/29
Dollars Obligated $1.3M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
The federal Project Grant award R21AI185033 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the APOBEC3B enzyme in the innate immune response against RNA viruses such as SARS-CoV-2, HIV-1, and Hepatitis B. The $228,435 award, effective January 2, 2025 through December 31, 2026, will fund research at the University of California, Irvine to identify novel...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $155,454 to Washington University to conduct research on the molecular basis of receptor interactions for Venezuelan Equine Encephalitis Virus (VEEV). The key objectives are to identify alternative entry receptors for VEEV beyond the recently discovered primary receptor LDLRAD3, and to improve the therapeutic potential...
This Project Grant award of $375,430 from the National Institutes of Health's Biomedical Research and Research Training program (CFDA 93.859) supports research to understand how viral pathogens hijack cellular DNA replication and repair machinery for their own benefit. The goal is to develop novel tools and methodologies to interrogate how viruses modulate host genome stability signals, localize to cellular DNA break sites, and tether themselves to these sites for long-term persistence. The...
This Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to measure and understand the molecular mechanisms of viral nucleocapsid self-assembly and disassembly. The $370,190 award, effective May 10, 2025 through March 31, 2030, will use a combination of quantitative experimental methods, including interferometric scattering microscopy and cryo-electron microscopy, to study...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $471,159 to the University of California, Irvine (UCI) to conduct research on the role of interferon lambda in alpha herpesvirus neuroinvasion. The research aims to elucidate the mechanisms of axonal responses to interferon lambda and their effects on viral invasion of the nervous system, as well as determine how these...
This $477,226 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to discover novel antiviral systems in microbial eukaryotes. The research will focus on understanding how the amoeba genus Acanthamoeba defends against giant viruses called Megavirales, and then expand that knowledge to other microbial eukaryotes. The project will leverage cutting-edge AI techniques and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $658,273 to the University of Massachusetts Medical School to study how Herpes Simplex Virus 1 (HSV-1) interacts with and regulates the NLRP1 inflammasome pathway in human skin cells. The key goals are to identify the mechanisms by which HSV-1 activates and inhibits the NLRP1 inflammasome, and to...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $502,043 in funding to Brandeis University. The research program aims to investigate how transition metals shape catalysis and allostery in metalloproteins, focusing on two key enzyme superfamilies: viral proteases and SAMHD1 dNTPases. The project will dissect the metal-dependent activities of viral proteases from...
This Project Grant award of $384,363.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Temple University in Philadelphia, PA. The goal of the research is to study the role of the PELLINO1 (PELI1) protein in regulating antiviral immunity in the skin epidermis, with a focus on herpes simplex virus infections. The researchers will use mouse models and human/mouse cell cultures to define...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $380,725 to the University of California, San Diego (UCSD) to conduct research on the molecular determinants of viral receptor-binding protein evolution. The key goals are to establish a molecular model for how viral receptor-binding proteins can gain new functions, understand the constraints on their evolution, and identify...

MECHANISMS OF ENZYME REGULATION BY VIPERIN IN THE CELLULAR ANTIVIRAL RESPONSE - PROJECT SUMMARY EUKARYOTIC CELLS HAVE DEVELOPED SOPHISTICATED DEFENSES AIMED AT LIMITING VIRAL REPLICATION AND THEREBY PREVENTING INFECTION FROM ESCALATING TO OTHER CELLS. THIS R35 MIRA APPLICATION WILL SUPPORT STUDIES TO UNDERSTAND HOW AT THE BIOCHEMICAL LEVEL VARIOUS CELLULAR METABOLIC PATHWAYS ARE REGULATED AS PART OF THE INNATE IMMUNE RESPONSE TO VIRAL INFECTION TO DISRUPT VIRUS REPLICATION. SUCH STUDIES ARE ESSENTIAL FOR DEVELOPING MORE EFFECTIVE ANTI-VIRAL THERAPEUTICS. OUR STUDIES WILL CENTER AROUND A KEY ENZYME IN THE ANTIVIRAL RESPONSE: VIPERIN (VIRUS INHIBITORY PROTEIN; ENDOPLASMIC RETICULUM-ASSOCIATED, INTERFERON-INDUCIBLE), WHICH IS STRONGLY UP-REGULATED IN VIRAL INFECTIONS AND HAS BEEN SHOWN TO RESTRICT THE INFECTIVITY OF A NUMBER OF IMPORTANT HUMAN VIRUSES INCLUDING INFLUENZA A, HIV AND HEPATITIS C. VIPERIN CATALYZES THE SYNTHESIS OF THE ANTIVIRAL NUCLEOTIDE 3'-DEOXY-3',4'-DIDEHYDRO-CTP (DDHCTP) FROM CTP BY A RADICAL SAM-DEPENDENT MECHANISM. DDHCTP HAS BEEN SHOWN TO HAVE ANTIVIRAL PROPERTIES AGAINST SOME RNA VIRUSES, E.G. FLAVIVIRUSES, WHERE IT ACTS AS A CHAIN-TERMINATING INHIBITOR OF THE VIRAL RNA POLYMERASE. HOWEVER, THIS OBSERVATION DOES NOT EXPLAIN THE MUCH BROADER ANTIVIRAL PROPERTIES OF VIPERIN THAT ARE ASSOCIATED WITH ITS NETWORK OF PROTEIN-PROTEIN INTERACTIONS WITH VIRAL PROTEINS, CELLULAR PROTEINS IMPORTANT FOR VIRAL REPLICATION, AND COMPONENTS OF INNATE IMMUNE SIGNALING PATHWAYS. BUILDING ON THE RESULTS OF OUR PREVIOUS NIH-SUPPORTED RESEARCH, WE WILL INVESTIGATE HOW VIPERIN ACTS TO REGULATE VARIOUS CELLULAR METABOLIC AND SIGNALING PATHWAYS THAT ARE IMPORTANT FOR ESTABLISHING THE ANTIVIRAL STATE. OUR STRATEGY IS TO FOCUS ON EXAMPLES OF VIPERIN'S INTERACTIONS WITH OTHER ENZYMES FOR WHICH THERE IS BOTH A WELL- VALIDATED BIOLOGICAL RESPONSE AND A CLEAR BIOCHEMICAL RATIONAL UNDERPINNING THE RESPONSE. OUR EXPERIMENTAL APPROACH WILL COMBINE DETAILED MECHANISTIC AND STRUCTURAL STUDIES ON PURIFIED ENZYMES WITH FUNCTIONAL STUDIES OF ENZYMES TRANSFECTED IN MAMMALIAN CELL LINES. AS PART OF THESE STUDIES, WE WILL INVESTIGATE HOW VIPERIN ENGAGES WITH UBIQUITIN LIGASES TO ACTIVATE INNATE IMMUNE SIGNALING PATHWAYS AND PROTEASOMAL DEGRADATION OF ENZYMES NECESSARY FOR VIRAL REPLICATION. WE WILL INVESTIGATE HOW VIPERIN DOWN-REGULATES FATTY ACID B-OXIDATION THROUGH ITS INTERACTIONS WITH THE MITOCHONDRIAL TRIFUNCTIONAL ENZYME (PROTEIN) COMPLEX. WE WILL ALSO INVESTIGATE HOW VIPERIN INTERACTS WITH ENZYMES IN THE CHOLESTEROL BIOSYNTHETIC PATHWAY TO DECREASE CELLULAR CHOLESTEROL, WHICH IS NECESSARY FOR ENVELOPED VIRUSES TO BUD FROM THE CELL MEMBRANE. THE ANTICIPATED OUTCOME OF THIS PROJECT IS A UNIFIED UNDERSTANDING OF THE BIOCHEMICAL MECHANISMS UNDERPINNING VIPERIN'S DIVERSE ANTIVIRAL FUNCTIONS.

Posted 6/28/24, 12:00 AM